Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Kyoung-Ah | - |
dc.contributor.author | Park, Ji-Young | - |
dc.date.accessioned | 2021-09-08T01:41:47Z | - |
dc.date.available | 2021-09-08T01:41:47Z | - |
dc.date.created | 2021-06-11 | - |
dc.date.issued | 2010-07 | - |
dc.identifier.issn | 0031-6970 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/116113 | - |
dc.description.abstract | Metronidazole has been reported to cause various drug interactions when co-administered with certain drugs. One possible mechanism for this action is through an inhibition of P-glycoprotein (P-gp). We have assessed the possible inhibitory effects of metronidazole on P-gp-mediated drug disposition in healthy subjects using fexofenadine as a P-gp substrate. This was a randomized, placebo-controlled, open-label, two-way crossover study involving 12 healthy male volunteers who were treated with metronidazole 500 mg or placebo three times daily for 7 days. On day 7, a single dose of fexofenadine 120 mg was given orally. Plasma levels of fexofenadine were measured and its pharmacokinetics assessed. Metronidazole did not affect the plasma concentration profiles and the pharmacokinetics of fexofenadine. The area under the time versus concentration curve of fexofenadine in the metronidazole phase (2075.7 ng h/mL) was similar to that of the placebo phase (1999.2 ng h/mL) (P = 0.356). Additionally, metronidazole did not affect the maximum plasma levels of fexofenadine (304.4 ng/mL for placebo vs. 293.2 ng/mL for metronidazole) (P = 0.423). The elimination half-life and oral clearance of fexofenadine were not affected by metronidazole treatment. These results show that metronidazole did not have any inhibitory effect on the pharmacokinetics of fexofenadine. The results of the present study provide evidence that metronidazole does not act as an inhibitor of P-gp-mediated disposition in humans. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER HEIDELBERG | - |
dc.subject | BUSULFAN | - |
dc.subject | METABOLISM | - |
dc.subject | CYCLOSPORINE | - |
dc.subject | ELEVATION | - |
dc.subject | EXCRETION | - |
dc.subject | THERAPY | - |
dc.subject | RAT | - |
dc.title | Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Ji-Young | - |
dc.identifier.doi | 10.1007/s00228-010-0797-2 | - |
dc.identifier.scopusid | 2-s2.0-77955565855 | - |
dc.identifier.wosid | 000278616400010 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, v.66, no.7, pp.721 - 725 | - |
dc.relation.isPartOf | EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | - |
dc.citation.title | EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | - |
dc.citation.volume | 66 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 721 | - |
dc.citation.endPage | 725 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | BUSULFAN | - |
dc.subject.keywordPlus | METABOLISM | - |
dc.subject.keywordPlus | CYCLOSPORINE | - |
dc.subject.keywordPlus | ELEVATION | - |
dc.subject.keywordPlus | EXCRETION | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | RAT | - |
dc.subject.keywordAuthor | Drug interaction | - |
dc.subject.keywordAuthor | Fexofenadine | - |
dc.subject.keywordAuthor | Metronidazole | - |
dc.subject.keywordAuthor | P-glycoprotein | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.